Your Health, We Care
Release date: 2024-08-28 14:31:56 Recommended: 154
Balversa is a new anti-cancer drug targeting FGFR, targeting urothelial carcinoma with specific gene mutations, accurately blocking tumor growth signals, and bringing new hope to patients.
Drug interactions of Balversa mainly include:
As a substrate of CYP3A4, the metabolism of Balversa may be inhibited by CYP3A4 inhibitors (such as clarithromycin), resulting in an increase in plasma concentrations and an increased risk of adverse reactions; In contrast, CYP3A4 inducers (e.g., rifampicin) may reduce plasma concentrations of Balversa and affect its efficacy.
Balversa has low solubility in an acidic environment, and when combined with gastric acid inhibitors (such as omeprazole), it may reduce its gastrointestinal absorption, thereby affecting the efficacy of the drug. Be aware of possible interactions when using these drugs.
After understanding the efficacy of Balversa, we need to pay attention to its drug interactions. In particular, CYP3A4 inhibitors/inducers may affect Balversa metabolism, leading to increased or diminished efficacy, and clinical manifestations such as worsening adverse effects or diminished efficacy need to be closely monitored.
When Balversa interacts with CYP3A4 inhibitors/inducers, it may produce the following two clinical manifestations:
CYP3A4 inhibitors may reduce the metabolic rate of Balversa, resulting in an increase in plasma drug concentrations, which may enhance drug efficacy and even cause toxicity; On the other hand, CYP3A4 inducers (e.g., rifampicin) may promote the metabolism of Balversa, reduce its plasma concentration, and weaken its efficacy.
Due to the instability of drug concentrations, patients may experience adverse reactions related to Balversa, such as gastrointestinal reactions (nausea, vomiting), skin reactions (rash, itching), etc., and these adverse reactions may become more severe or frequent due to high or low drug concentrations.
In the face of the interaction of Balversa with CYP3A4 inhibitors/inducers, patients may have clinical manifestations of abnormal drug efficacy. To cope with this, it is advisable to adjust the dose or change the relevant medication and closely monitor the condition for changes.
Responses to the interaction of Balversa with CYP3A4 inhibitors/inducers include:
Try to avoid concomitant use of Balversa with strong inhibitors or inducers of CYP3A4. If it must be combined, the dose of Balversa should be carefully adjusted according to the pharmacokinetic properties of the drug and the specific situation of the patient to maintain its therapeutic effect and reduce adverse effects.
During the combination period, patients were closely monitored for drug efficacy and adverse reactions, and changes in CYP3A4 enzyme activity were regularly assessed. If drug interactions are found to be less effective or have increased adverse reactions, you should communicate with your doctor in time to adjust your treatment regimen.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
